Lyell Immunopharma, Inc. filed a Form 8-K on September 10, 2026, disclosing the completion of a technology transfer for its LYL273 product candidate to the company's LyFE Manufacturing Facility in Bothell, Washington, along with an updated timeline for the ongoing Phase 1/2 clinical trial in metastatic colorectal cancer.

Key Highlights

  • Manufacturing transfer complete: Lyell Immunopharma disclosed the completion of the technology transfer for LYL273 to its LyFE Manufacturing Facility in Bothell, Washington.
  • Trial update included: The company also provided an updated timeline on the Phase 1/2 trial evaluating LYL273.
  • Target indication: LYL273 is described as a next-generation guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate for relapsed/refractory metastatic colorectal cancer and other GCC-expressing cancers.
  • Press release filed: A press release dated September 10, 2026, titled "Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer," was filed as Exhibit 99.1.
  • Signatory: The filing was signed by Mark Meltz, General Counsel of Lyell Immunopharma, Inc.

LYL273 Technology Transfer and Phase 1/2 Trial Timeline Update

According to the filing, Lyell Immunopharma, Inc. (NASDAQ:LYEL) issued a press release on September 10, 2026, announcing that it had completed the technology transfer for LYL273 to the company's proprietary LyFE Manufacturing Facility located in Bothell, Washington. The filing describes LYL273 as the company's "next-generation guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate for the treatment of relapsed/refractory metastatic colorectal cancer and other GCC-expressing cancers."

In addition to the manufacturing milestone, the company disclosed an updated timeline for the Phase 1/2 clinical trial evaluating LYL273 in metastatic colorectal cancer. The filing does not provide specific revised dates or interim trial data within the 8-K body; the full details are contained in the press release filed as Exhibit 99.1 and incorporated by reference.

The 8-K was filed under Item 8.01 (Other Events) and signed by Mark Meltz, the company's General Counsel, on September 10, 2026. Lyell Immunopharma is incorporated in Delaware and headquartered at 201 Haskins Way, South San Francisco, California 94080. Its common stock, with a par value of $0.0001 per share, is listed on The Nasdaq Global Select Market under the trading symbol LYEL.

What Was Disclosed

Lyell Immunopharma filed an 8-K on September 10, 2026, reporting the completion of the LYL273 manufacturing technology transfer to its Bothell, Washington facility and an updated Phase 1/2 trial timeline, with full details contained in the attached press release.